- The FDA granted Breakthrough Device Designation to the Fenestrated TREO® system.
- The designation aims to fast-track regulatory review for life-threatening conditions.
- Fenestrated TREO® is designed for complex abdominal aortic aneurysms.
- It offers a customized solution for challenging anatomies.
FDA Breakthrough Device Designation
The US FDA has granted Breakthrough Device Designation to the Fenestrated TREO® Abdominal Stent-Graft system. This designation is part of a program designed to expedite the regulatory review process for medical technologies that offer more effective treatment or diagnosis for life-threatening or irreversibly debilitating conditions.
Purpose of the Designation
The Breakthrough Device Designation aims to provide patients and healthcare professionals with timely access to important medical devices by accelerating their development, assessment, and review. This is particularly crucial for devices that address significant unmet medical needs.
About Fenestrated TREO®
Fenestrated TREO® is a custom-made endovascular stent-graft system developed to treat complex abdominal aortic aneurysms (AAA). It is intended for the endovascular repair of juxtarenal and suprarenal abdominal aortic and aorto-iliac aneurysms, especially in cases where standard devices may not fit adequately.
Benefits and Customization
The device offers a tailored, minimally invasive solution for challenging anatomies. It can incorporate multiple fenestrations precisely aligned to a patient's unique arterial branching pattern, addressing the needs of patients with complex vessel configurations that standard devices cannot accommodate.
